Cargando…

Everolimus in metastatic renal cell carcinoma patients intolerant to previous VEGFr-TKI therapy: a RECORD-1 subgroup analysis

BACKGROUND: A relevant percentage of patients with metastatic renal cell carcinoma develop intolerance to vascular endothelial growth factor receptor-tyrosine kinase inhibitors (VEGFr-TKIs) and require careful selection of subsequent treatment. This retrospective analysis evaluated the safety and ef...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bracarda, S, Hutson, T E, Porta, C, Figlin, R A, Calvo, E, Grünwald, V, Ravaud, A, Motzer, R, Kim, D, Anak, O, Panneerselvam, A, Escudier, B
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2012
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3341863/ https://www.ncbi.nlm.nih.gov/pubmed/22441644 http://dx.doi.org/10.1038/bjc.2012.89

Ejemplares similares

Outcomes in Patients With Metastatic Renal Cell Carcinoma Who Develop Everolimus-Related Hyperglycemia and Hypercholesterolemia: Combined Subgroup Analyses of the RECORD-1 and REACT Trials
por: Bono, Petri, et al.
Publicado: (2016)

Meta-analysis of stomatitis in clinical studies of everolimus: incidence and relationship with efficacy
por: Rugo, H. S., et al.
Publicado: (2016)

Tivozanib in Patients with Advanced Renal Cell Carcinoma Previously Treated with Axitinib: Subgroup Analysis from TIVO-3
por: Meza, Luis, et al.
Publicado: (2022)

Management of VEGFR-Targeted TKI for Thyroid Cancer
por: Enokida, Tomohiro, et al.
Publicado: (2021)

Long-term follow-up of overall survival for cabozantinib versus everolimus in advanced renal cell carcinoma
por: Motzer, Robert J., et al.
Publicado: (2018)

Addition of Everolimus Post VEGFR Inhibition Treatment Failure in Advanced Sarcoma Patients Who Previously Benefited from VEGFR Inhibition: A Case Series
por: ElNaggar, Adam C., et al.
Publicado: (2016)

Q-TWiST analysis to estimate overall benefit for patients with metastatic renal cell carcinoma treated in a phase III trial of sunitinib vs interferon-α
por: Patil, S, et al.
Publicado: (2012)

Aneurysm and Artery Dissection After Oral VEGFR-TKI Use in Adults With Cancer
por: Kang, Soyoung, et al.
Publicado: (2023)

Everolimus Use for Intolerance or Failure of Baseline Immunosuppression in Adult Heart and Lung Transplantation
por: Kelsh, Shelby E., et al.
Publicado: (2018)

Sorafenib tolerability in elderly patients with advanced renal cell carcinoma: results from a large pooled analysis
por: Procopio, G, et al.
Publicado: (2013)

Efficacy and safety of sunitinib in elderly patients with metastatic renal cell carcinoma
por: Hutson, T E, et al.
Publicado: (2014)

Study of Cathepsin B inhibition in VEGFR TKI treated human renal cell carcinoma xenografts
por: Chen, Chun-Hau, et al.
Publicado: (2019)

Nivolumab versus everolimus in advanced renal cell carcinoma: Japanese subgroup analysis from the CheckMate 025 study
por: Tomita, Yoshihiko, et al.
Publicado: (2017)

Case Report: Gastrointestinal PEComa With TFE3 Rearrangement Treated With Anti-VEGFR TKI Apatinib
por: Xu, Jiaming, et al.
Publicado: (2020)

The efficacy of VEGFR TKI therapy after progression on immune combination therapy in metastatic renal cell carcinoma
por: Barata, Pedro Coelho, et al.
Publicado: (2018)

Extended therapy breaks from VEGFR TKI therapy in renal cell carcinoma: Sometimes less is more
por: Zahoor, Haris, et al.
Publicado: (2017)

Crosstalk between VEGFR and other receptor tyrosine kinases for TKI therapy of metastatic renal cell carcinoma
por: Lai, Yongchang, et al.
Publicado: (2018)

Mediating EGFR-TKI Resistance by VEGF/VEGFR Autocrine Pathway in Non-Small Cell Lung Cancer
por: Osude, Chike, et al.
Publicado: (2022)

Delayed Diagnosis and Multi-TKI Intolerance: A Case Report of CML Concurrent With COVID-19
por: Luan, Chengxin, et al.
Publicado: (2022)

A phase 1b clinical trial of the multi-targeted tyrosine kinase inhibitor lenvatinib (E7080) in combination with everolimus for treatment of metastatic renal cell carcinoma (RCC)
por: Molina, Ana M., et al.
Publicado: (2013)

Long-term response with everolimus for metastatic renal cell carcinoma refractory to sunitinib
por: Molina, Ana M., et al.
Publicado: (2010)

Quality-adjusted Time Without Symptoms or Toxicity (Q-TWiST) for Lenvatinib plus Everolimus Versus Everolimus Monotherapy in Patients with Advanced Renal Cell Carcinoma
por: Lee, Chung-Han, et al.
Publicado: (2021)

Inhibition of ALK1 signaling with dalantercept combined with VEGFR TKI leads to tumor stasis in renal cell carcinoma
por: Wang, Xiaoen, et al.
Publicado: (2016)

PI3K-AKT-mTOR pathway alterations in advanced NSCLC patients after progression on EGFR-TKI and clinical response to EGFR-TKI plus everolimus combination therapy
por: Fang, Wenfeng, et al.
Publicado: (2020)

Second-Generation Tyrosine Kinase Inhibitors (Tki) as Salvage Therapy for Resistant or Intolerant Patients to Prior TKIs
por: Breccia, Massimo, et al.
Publicado: (2014)

Impact of Prior Chemotherapy Use on the Efficacy of Everolimus in Patients With Advanced Pancreatic Neuroendocrine Tumors: A Subgroup Analysis of the Phase III RADIANT-3 Trial
por: Lombard-Bohas, Catherine, et al.
Publicado: (2015)

Combination VEGFR/immune checkpoint inhibitor therapy: a promising new treatment for renal cell carcinoma
por: Lee, Chung-Han, et al.
Publicado: (2018)

Investigation of novel circulating proteins, germ line single-nucleotide polymorphisms, and molecular tumor markers as potential efficacy biomarkers of first-line sunitinib therapy for advanced renal cell carcinoma
por: Motzer, Robert J., et al.
Publicado: (2014)

Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma
por: Powles, Thomas, et al.
Publicado: (2021)

Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms
por: Grünwald, Viktor, et al.
Publicado: (2023)

Correction to: Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma
por: Powles, Thomas, et al.
Publicado: (2021)

PD-L1 Upregulation by the mTOR Pathway in VEGFR-TKI–Resistant Metastatic Clear Cell Renal Cell Carcinoma
por: Jeong, Se Un, et al.
Publicado: (2023)

Treatment of everolimus-resistant metastatic renal cell carcinoma with VEGF-targeted therapies
por: Grünwald, V, et al.
Publicado: (2011)

Salvage lenvatinib/everolimus combination therapy after immune checkpoint inhibitor and VEGFR tyrosine kinase inhibitor for metastatic renal cell carcinoma
por: Kwok, Christopher, et al.
Publicado: (2023)

Tivozanib: is total VEGFR inhibition the way to success in terms of tolerability and efficacy in advanced kidney cancer?
por: Gross-Goupil, Marine, et al.
Publicado: (2012)

Outcomes based on prior therapy in the phase 3 METEOR trial of cabozantinib versus everolimus in advanced renal cell carcinoma
por: Powles, Thomas, et al.
Publicado: (2018)

Outcomes based on age in the phase III METEOR trial of cabozantinib versus everolimus in patients with advanced renal cell carcinoma
por: Donskov, Frede, et al.
Publicado: (2019)

Prognostic factors for survival in 1059 patients treated with sunitinib for metastatic renal cell carcinoma
por: Motzer, R J, et al.
Publicado: (2013)

Everolimus in advanced, progressive, well‐differentiated, non‐functional neuroendocrine tumors: RADIANT‐4 lung subgroup analysis
por: Fazio, Nicola, et al.
Publicado: (2017)

COMPARZ Post Hoc Analysis: Characterizing Pazopanib Responders With Advanced Renal Cell Carcinoma
por: Sternberg, Cora N., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_ht5c0nrd5e2ftdj9mkjt45ccpm